Antithrombotic therapy before, during and after transcatheter aortic valve replacement (TAVR)

Abhishek Sharma, Sunny Goel, Carl J. Lavie, Armin Arbab-Zadeh, Debabrata Mukherjee, Jason Lazar

Research output: Contribution to journalArticlepeer-review

Abstract

Transcatheter aortic valve replacement (TAVR) has been emerged as a promising alternative for the management of patients with severe AS who otherwise are deemed inappropriate candidates for surgery. Post procedural thromboembolic events and risk of bleeding continue to be a significant challenge in managing patients who underwent TAVR. This article systematically reviews the evidence, current guidelines and upcoming studies investigating antithrombotic therapy before, during and after TAVR.

Original languageEnglish (US)
Pages (from-to)467-473
Number of pages7
JournalJournal of Thrombosis and Thrombolysis
Volume39
Issue number4
DOIs
StatePublished - May 1 2015

Keywords

  • Dual antiplatelet therapy (DAPT)
  • Transcatheter aortic valve replacement (TAVR)

ASJC Scopus subject areas

  • Hematology
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Antithrombotic therapy before, during and after transcatheter aortic valve replacement (TAVR)'. Together they form a unique fingerprint.

Cite this